{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Serious Adverse Events (SAEs)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"37"}]}],"title":"Adverse Events (AEs)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"description":"Number of participants with toxicities of Thalidomide/Dexamethasone vs. VAD as induction regimens in newly diagnosed multiple myeloma (MM).","groups":[{"description":"VAD (vincristine, adriamycin, dexamethasone). Vincristine and adriamycin was administered by continuous infusion via a venous catheter for 96 hours every 28 days. Each 28 days is considered one \"cycle\" of therapy. Patients were to receive 4 to 6 cycles of therapy. Dexamethasone was taken in pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4. Patients were randomized to receive zoledronic acid IV on either Day 1 or 15 of each cycle.","id":"OG000","title":"Active Comparator: VAD Treatment"},{"description":"Thalidomide was taken orally once every day in the evening for four to six months. The dexamethasone was taken in a pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4.","id":"OG001","title":"Active Comparator: Thalidomide and Dexamethasone Treatment"}],"paramType":"NUMBER","populationDescription":"All evaluable participants","reportingStatus":"POSTED","timeFrame":"4 Years, 7 Months","title":"Number of Participants With Adverse Events, by Group","type":"SECONDARY","unitOfMeasure":"participants"}